Altogether, SFN provides a strong proof of concept for dietary-derived Nrf2 activation in ALS, though clinical translation will depend on overcoming pharmacological limitations through innovative formulation strategies. The gene discussed is NFE2L2; the disease is amyotrophic lateral sclerosis.